Watch Dr Komrokji discuss present and possible future treatments for HR-MDS and AML
- Current treatment options offer limited durability and short median durations of response1,2
- With few treatment advances, patients with HR-MDS remain at risk for transformation to AML3
- “An immunotherapeutic approach for myeloid diseases, or immuno-myeloid therapy, may be a promising way to address immune dysfunction”
—Rami Komrokji, MD
Scroll for more
Rami Komrokji, MD, Vice Chair,
Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
“An immunotherapeutic approach for myeloid diseases, or immuno-myeloid therapy, may be a promising way to address immune dysfunction”
—Rami Komrokji, MD
- An immuno-myeloid approach harnesses the immune system to eliminate malignant myeloid cells in patients with HR-MDS and AML
Current treatments offer limited durability and short median durations of response1,2
- Median duration of response is ~13 months with HMAs in patients with HR-MDS and 17.5 months with an HMA/BCL-2 combination in patients with AML1,2
- OS is as low as 9.6 months in patients with HR-MDS with a very high-risk IPSS-R score and is <12 months in patients with AML3-5
- Longer durations of HMA treatment have shown better outcomes, but only 37% of patients remain on therapy for <12 courses6
With few treatment advances, patients with HR-MDS remain at risk for transformation to AML3
- 1 in 4 patients will develop AML after a median duration of 8.8 to 16.7 months3